Interferon as a treatment for uveitis associated with multiple sclerosis

Becker, Matthias

doi:10.1136/bjo.2004.061119

Cited by 114 publications

(52 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these patients secondary changes like the formation of cystoid macular edema or occlusive vasculitis often develop [17,18,19]. If these rare secondary changes occur, the disease is often difficult to manage and requires high doses of corticosteroids [23] or laser treatment [24,25,26]. All of our uveitic patients had intermediate uveitis, and none developed sight-threatening complications such as macular edema or retinal periphlebitis.…”

Section: Discussionmentioning

confidence: 99%

“…The study of Becker et al [24] suggested that the treatment of MS-associated uveitis with interferon (IFN)-β may improve intraocular inflammatory activity as well as reduce vascular leakage, and hence the presence of cystoid macular edema, thus improving BSCVA. IFN has been shown to have beneficial effects in patients with MS [25] and/or optic neuritis [26].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pattern of Uveitis in an Egyptian Population with Multiple Sclerosis: A Hospital-Based Study

2012

View full text Add to dashboard Cite

Purpose: To investigate the prevalence and pattern of uveitis in patients with multiple sclerosis (MS). PatientsandMethods: This is a cross-sectional, observational, descriptive clinical study of patients with MS who had complete ophthalmological examination. Data collected comprised demographics of the patients and complete ocular examination findings. Exclusion criteria were history of ocular surgery, trauma or diagnosis of any other ocular pathology. Results: Seventy-five patients with a mean age of 32.64 years (ranging from 16 to 50) diagnosed with MS of the relapsing-remitting type were included in this study. There were 34 males and 41 females, a ratio of 5:6. The mean duration of the MS disease was 5.6 years. Eight eyes of 7 patients with a mean age of 20 years had intermediate uveitis, of which 5 were males. Out of the 7 patients, 5 had exacerbated MS, and 2 were in remission; 4 had relative afferent pupillary defect. In the 8 eyes with uveitis, 6 had a best spectacle-corrected visual acuity (BSCVA) of 1, 1 had a BSCVA of 0.5 and 1 had a BSCVA of 0.25. Conclusion: Uveitis occurs in about 10% of patients with MS affecting younger males with exacerbated disease. Most inflammations of the uveitic MS patients were in the form of intermediate uveitis that was controlled with medication with no visual threatening complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pattern of Uveitis in an Egyptian Population with Multiple Sclerosis: A Hospital-Based Study

2012

View full text Add to dashboard Cite

show abstract

“…In our patient population, uveitis was typically of the granulomatous type, bilateral and located at either the anterior or intermediate regions of the eye, leading to dense vitreous opacifications, retinal periphlebitis, intraretinal hemorrhages and retinal vascular proliferations, thus forming a literally pathognomonic clinical picture. MS-associated uveitis seems to respond very well to interferon therapy, and therefore early diagnosis could spare the patient sight-threatening complications [18][19][20][21].…”

Section: Discussionmentioning

confidence: 98%

Uveitis and neurologic diseases: an often overlooked relationship

Maca

Scharitzer

Barisani-Asenbauer

2006

Wien Klin Wochenschr

View full text Add to dashboard Cite

Several diseases can cause both ocular and/or central nervous system inflammation. This should prompt ophthalmologists and neurologists in the presence of one to rule out the other. In uveitis patients without evident neurological symptoms, specific ocular pathologies can help the treating ophthalmologist to tailor the work-up, whereas neurologists should always screen their patients, even when they are asymptomatic for ocular disease. Early diagnosis in both cases can help to initiate adequate treatment, thereby modulating the course of the disease and preventing complications.

show abstract

“…16 Becker ve ark. 17 On üç hastalık olgu serilerinde IFNβ-1a'nın üveitle birlikte olan MS hastalarında intraoküler aktiviteyi baskılamakta etkin olduğunu ve görme keskinliğinde artış yönünde olumlu etkisi olduğu bildirilmiştir. Bu çalışmada da hastaların biri hariç diğerlerinin bir kez atak geçirmesini ve görmeyi 0,5'in altına düşürecek ciddi komplikasyonların yaşanmamasını hastaların IFN β-1a tedavisi altında olmasına bağlamaktayız Sonuç olarak MS ve üveit birlikteliği çok sık olmamakta, kolayca gözden kaçabilmektedir.…”

Section: Discussionunclassified

Multipl Skleroz ile İlişkili Üveitler

...

2012

tjo

View full text Add to dashboard Cite

ÖzetAmaç: Multipl sklerozlu (MS) hastalarda gelişen üveitin klinik bulgularını ve sonuçlarını değerlendirmek. Ge reç ve Yön tem: 2005-2011 yılları arasında üveit polikliniğine başvuran multipl sklerozu ve üveiti olan sekiz hastanın kayıtları retrospektif olarak incelendi. Sonuçlar: Başvuru sırasında sekiz hastanın (Yedi kadın, bir erkek; ortalama yaş 39±7,5 yıl; ortalama izlem süresi 3,8±1,8 yıl) on üç gözünün ortalama görme keskinliği 0,7±0,2 idi. İki hastaya MS ile ilişkili ön üveit, beş hastaya intermedier üveit ve retinal vaskülit, bir hastaya retinal vaskülit tanısı konuldu. Takip boyunca tüm hastalar interferon β-1a tedavisi altındaydı. Hastaların üveit tedavileri hastalığın lokalizasyonuna göre yapıldı. Takip sonunda bir olgu dışında tüm hastaların görme keskinliği tam olarak korundu. Tar t›fl ma: Sistemik interferon β-1a uygulanan hastalarda üveit tedavi ile kontrol altına alınabilmekte, sık rekürrensler ve kalıcı görme kayıpları önlenebilmektedir. ( Re sults: The mean visual acuity of the thirteen eyes of eight patients (seven women, one man; mean age 39±7.5 years; mean follow-up 3.8±1.8 years) was 0.7±0.2 at the time of presentation. Two patients were diagnosed as anterior uveitis related with MS, five patients as intermediate uveitis and retinal vasculitis, and one patient as retinal vasculitis alone. All patients received interferon β-1a during the follow-up. The uveitis treatment was applied according to the localization of the disease. Except in one, the visual acuity was restored in all patients at the end of follow-up. Dis cus si on: Uveitis can be taken under control and recurrences and permanent visual loss can be prevented in patients treated with interferon β-1a. ( Gi riflMultipl skleroz (MS) santral sinir sisteminin otoimmün olduğu düşünülen kronik, inflamatuar, demiyelinizan bir hastalığıdır. 1 Multipl skleroz sıklıkla fokal ve multifokal rekürren ataklar halinde nörolojik disfonksiyonlar ve santral sinir sistemi lezyonlarıyla kendini gösterir. Multipl sklerozlu hastalarda en sık görülen göz bulgusu optik nörittir, %30 sıklığında görülür. 2,3 Multipl sklerozlu hastalarda semptomatik intraoküler enflamasyon daha seyrek görülür (%1) ve MS'le birlikte en sık görülen üveit intermedier ve arka üveittir, ön üveit ve panüveitler daha az sıklıkta görülür. 4

show abstract

Interferon as a treatment for uveitis associated with multiple sclerosis

Cited by 114 publications

References 21 publications

Pattern of Uveitis in an Egyptian Population with Multiple Sclerosis: A Hospital-Based Study

Pattern of Uveitis in an Egyptian Population with Multiple Sclerosis: A Hospital-Based Study

Uveitis and neurologic diseases: an often overlooked relationship

Multipl Skleroz ile İlişkili Üveitler

Contact Info

Product

Resources

About